CD274 and esophageal adenocarcinoma: In the PERFECT trial, the feasibility and efficacy of nCRT combined with atezolizumab (a PD-L1 inhibitor) for resectable esophageal adenocarcinoma was investigated, with a pCR rate was 25%.